Table 4.
Proportion of symptomatic TEs according to the type of chemotherapy regimen
| % (n/N) | (95% CI) | ||
|---|---|---|---|
| Thromboembolic events | Nadroparin | Placebo | Relative risk |
| Overall PROTECHT population | 2 (15/769) | 3.9 (15/381) | 0.5 (0.24-1.00) |
| Chemotherapy regimen containing: | |||
| 5-Fluorouracil | 2.5 (7/285) | 3.3 (5/151) | 0.74 (0.24-2.30) |
| Cisplatin | 2.3 (4/177) | 7.0 (6/86) | 0.32 (0.09-1.12) |
| Gemcitabine | 2.6 (4/156) | 8.1 (7/86) | 0.32 (0.09-1.05) |
| Oxaliplatin | 0.7 (1/143) | 1.1 (1/89) | 0.62 (0.04-9.83) |
| Docetaxel | 1.4 (2/142) | 4.5 (3/67) | 0.31 (0.05-1.84) |
| Carboplatin | 0.8 (1/119) | 5.5 (3/55) | 0.15 (0.02-1.45) |
| Epirubicin | 0.0 (0/54) | 8.3 (2/24) | ND |
| Adriamycin | 0.0 (0/25) | 5.3 (1/19) | ND |
| Irinotecan | 3.1 (3/96) | 0.0 (0/41) | ND |
| Vinca alkaloids | 2.2 (2/90) | 3.7 (1/27) | 0.60 (0.06-6.36) |
| Capecitabine | 0.0 (0/61) | 3.3 (1/30) | ND |
| Etoposide | 2.4 (1/41) | 11.8 (2/17) | 0.21 (0.02-2.14) |
| Cyclophosphamide | 0.0 (0/33) | 5.6 (1/18) | ND |
| Previous Chemotherapy | |||
| Naïve | 2.5 (10/405) | 5.2 (11/213) | 0.48 (0.21-1.11) |
| Non-naïve | 1.4 (5/364) | 2.4 (4/168) | 0.58 (0.16-2.12) |
No TE events were observed among patients receiving trastuzumab, cetuximab, bevacizumab, liposomal doxorubicin or mitomycin. Abbreviation: ND, not determinable.